Dendreon was founded in 1992 by Stanford Medical School researchers, to develop cell activation therapy for the treatment of prostate and other cancers. Dendreon is focused on the development and commercialization of immunologically based therapeutic products. Key elements of this business strategy include: maximizing speed to market of lead therapeutic vaccines, building a large and diverse product portfolio, retaining core commercialization rights, developing key collaborative agreements and effectively leveraging its proprietary technologies.